FDA’s Pharmacy Compounding Advisory Committee completed its peptide review by recommending Semax and Epitalon for the 503A Bulks List and rejecting Emideltide, leaving six of seven reviewed peptides with favorable recommendations.
Korean translation
FDA 약국조제자문위원회가 펩타이드 심의를 마쳐 Semax와 Epitalon의 503A 원료목록 등재를 권고하고 Emideltide는 부결해, 검토 대상 7종 중 6종이 긍정 권고를 받음.